Curis, Inc. (CRIS) Price Prediction 2026–2050

Curis, Inc. is a biotechnology company that engages in the discovery and development of drug candidates for the treatment of human cancers in the United States.

Its clinical pipeline includes Emavusertib, an oral small-molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single-arm expansion trial in patients with relapsed/refractory primary central nervous system lymphoma. The pipeline also features Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small-molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3.

It has collaboration agreements with Genentech Inc., or Genentech and F. Hoffmann-La Roche Ltd, or Roche, for the commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma, or BCC; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and also licensed three programs under the Aurigene collaboration, including emavusertib. Curis, Inc.

was incorporated in 2000 and is headquartered in Lexington, Massachusetts.

Curis, Inc. (CRIS) is a biotechnology company focused on oncology, with a current price of $5.29 and a market cap of $10.31M. It is ranked 5128 by market capitalization among its peers.

The asset has a 30-day forecast profile that suggests a path for price movement over time, with an average forecast in 2026 of $5.29, rising to $7.17 by 2030 and $17.36 by 2050. These figures come with corresponding min/max ranges and ROIs at each horizon, reflecting varying potential outcomes and sentiment levels.

Overall, the outlook shows a bullish tilt for the long horizon starting around 2030 and extending through 2050, though actual results will depend on clinical progress, regulatory factors, and market conditions.

2030 brings a notable bullish signal, with an average forecast price of $7.17, a min of $4.43, a max of $12.44, and a ROI of 35.5%, reflecting a bullish sentiment. The 2031 forecast remains bullish with an average of $7.17, a min of $4.24, a max of $12.89, and a ROI of 35.6%.

Looking further, 2040 offers an average of $6.43 with a min of $2.89 and a max of $14.12, delivering a ROI of 21.6% and a bullish sentiment. By 2050 the forecast strengthens sharply to an average of $17.36, a min of $7.81, a max of $39.94, and a ROI of 228.2%, with a bullish outlook continuing.

These are projection ranges and are not guarantees; the long-run path for Curis depends on drug development outcomes, regulatory decisions, and market dynamics in oncology. Investors should view these figures as directional estimates rather than certainties.